CRISPR Therapeutics Surges to 314th in Trading Volume with $249 Million Day

On June 18, 2025, CRISPR Therapeutics (CRSP) saw a significant surge in trading volume, reaching $249 million, marking a 46.92% increase from the previous day. This surge placed the company at the 314th position in terms of trading volume for the day. The stock price of CRISPR Therapeutics rose by 2.80%, marking the fourth consecutive day of gains, with a total increase of 7.56% over the past four days.

CRISPR Therapeutics is a pioneer in gene-editing technology, with a market capitalization of $3.96 billion. The company's stock performance has been closely watched, with a current price of $44.43, reflecting a 52-week range of $31.27 to $62.75. Despite the recent gains, the stock has faced challenges, with a decline of over 44% in the past year. However, the company's gene-editing therapy, exagamglogene autotemcel (Casgevy), has received FDA approval for treating sickle cell disease and transfusion-dependent beta thalassemia, providing a significant boost to its prospects.

Analysts have noted that CRISPR Therapeutics' CTX112 cell therapy is performing well in oncology and autoimmune disease trials. The company's earnings estimates for the next fiscal year indicate a change of +22.4% from what was reported a year ago, suggesting a positive outlook for future growth. The consensus earnings estimate of $4.3 reflects a strong potential for the company to rebound from its recent setbacks.

CRISPR Therapeutics' strategic partnerships and ongoing clinical trials are expected to drive future growth. The company's collaboration with Vertex Pharmaceuticals on Casgevy and its ongoing trials for CTX112 and other therapies position it well for long-term success. The gene-editing market is projected to grow at a compound annual growth rate of 15.7%, reaching $40.1 billion by 2034, creating significant opportunities for CRISPR Therapeutics and other players in the field.